Trastuzumab (International)
In the US, Trastuzumab (trastuzumab systemic) is a member of the drug class HER2 inhibitors and is used to treat Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer - Metastatic, Esophageal Carcinoma, Gastric Cancer and Salivary Gland Cancer.
US matches:
- Trastuzumab
- Trastuzumab and hyaluronidase-oysk
- Trastuzumab-anns
- Trastuzumab-dkst
- Trastuzumab-dttb
- Trastuzumab-pkrb
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L01XC03
CAS registry number (Chemical Abstracts Service)
0180288-69-1
Chemical Formula
C6470-H10012-N1726-O2013-S42
Therapeutic Categories
Antineoplastic agent
Biological response modifier, BRM
Immunomodulator
Anti-HER2 monoclonal antibody
Chemical Name
Immunoglobulin G1 (human-mouse monoclonal rhuMab HER2γ₁-chain antihuman p185c-erbB²receptor), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer (WHO )
Foreign Names
- Trastuzumabum (Latin)
- Trastuzumab (German)
- Trastuzumab (French)
- Trastuzumab (Spanish)
Generic Names
- Trastuzumab (OS: BAN, USAN, DCF)
- Trastuzumab (Genetical Recombination) (OS: JAN)
- Anti-HER-2 monoclonal antibody (IS)
- MAB anti-HER-2 (IS)
- UNII-P188ANX8CK (IS)
- Trastuzumab Emtansine (OS: USAN)
- Trastuzumab Emtansine (Genetical Recombination) (OS: JAN)
- ado-Trastuzumab emtansine (IS)
- PRO 132365 (IS)
- T-DM 1 (IS)
- Trastuzumab-MCC-DM 1 (IS)
- UNII-SE2KH7T06F (IS)
Brand Names
- Herceptin
Chugai Pharmaceutical, Japan; F. Hoffmann-La Roche LTD, Serbia; Genentech, Georgia; Genentech, United States; Genentech Inc., Oman; Hoffmann La Roche, Kuwait; Hoffmann-La Roche, Canada; Hoffmann-La Roche Ltd, Latvia; Productos Roche, Chile; Roche, Armenia; Roche, Argentina; Roche, Bosnia & Herzegowina; Roche, Belgium; Roche, Brazil; Roche, Colombia; Roche, Cyprus; Roche, Czech Republic; Roche, Germany; Roche, Denmark; Roche, Ecuador; Roche, Estonia; Roche, Egypt; Roche, Spain; Roche, Finland; Roche, France; Roche, Georgia; Roche, Greece; Roche, Hong Kong; Roche, Croatia (Hrvatska); Roche, Ireland; Roche, Italy; Roche, Lebanon; Roche, Lithuania; Roche, Moldova; Roche, Myanmar; Roche, Mexico; Roche, Norway; Roche, New Zealand; Roche, Peru; Roche, Philippines; Roche, Poland; Roche, Paraguay; Roche, Russian Federation; Roche, Sweden; Roche, Thailand; Roche, Tunisia; Roche, Turkey; Roche, Taiwan; Roche, Venezuela; Roche, Vietnam; Roche, South Africa; Roche Pharmaceutical, China; Roche Products, Australia; Roche Products, United Kingdom; Roche Registration, Netherlands; Roche Registration, Romania; Roche Registration Limited, Iceland; Roche Registration, Slovenia; Roche Uruguay, Uruguay - Herceptin 150mg
Haemato Pharm, Austria; Inopha, Austria; Orifarm, Austria; Roche, Hungary; Roche, Luxembourg; Roche Registration, Austria; Roche Pharma Schweiz, Switzerland - Herceptin 440mg
Roche Pharma Schweiz, Switzerland - Herceptin 600mg
Abacus, Austria; Haemato Pharm, Austria; Orifarm, Austria; Roche, Hungary; Roche Registration, Austria - Herceptin 600mg/5ml
Roche, Luxembourg; Roche Pharma Schweiz, Switzerland - Herceptin SC
Productos Roche, Chile; Roche, New Zealand; Roche Products, Australia - Herceptin SC 600mg/5ml
Roche, Israel - Hertraz
Biocon, Georgia - Herzuma
Celltrion, Slovenia - Kadcyla
Productos Roche, Chile; Roche, Bosnia & Herzegowina; Roche, Cyprus; Roche, Croatia (Hrvatska); Roche, Poland; Roche, Turkey; Roche Farma, Peru; Roche Registration Limited, Iceland - Kadcyla 160mg
Roche, Hungary - Kanjinti
Amgen Europe, Netherlands; Amgen Europe, Slovenia - Ontruzant
Samsung Bioepis, Latvia; Samsung Bioepis UK, Netherlands - Perjeta-Herceptin [+ Pertuzumab]
Hoffmann-La Roche, Canada - Trastuzumab Baxter
Baxter, New Zealand - Zedora
Libbs, Brazil - Kadcyla
Chugai Pharmaceutical, Japan; DSM Pharmaceuticals, Georgia; F. Hoffmann-La Roche LTD, Serbia; Genentech, United States; Hoffmann-La Roche, Canada; Roche, Argentina; Roche, Belgium; Roche, Brazil; Roche, Czech Republic; Roche, Germany; Roche, Denmark; Roche, Estonia; Roche, Spain; Roche, Finland; Roche, France; Roche, Hong Kong; Roche, Ireland; Roche, Israel; Roche, Lithuania; Roche, Norway; Roche, New Zealand; Roche, Oman; Roche, Sweden; Roche Products, Australia; Roche Products, United Kingdom; Roche Registration, Netherlands; Roche Registration, Romania; Roche Registration Ltd, Greece; Roche Registration, Slovenia - Kadcyla 100mg
Orifarm, Austria; Roche, Hungary; Roche, Luxembourg; Roche Registration, Austria; Roche Pharma Schweiz, Switzerland - Kadcyla 160mg
Orifarm, Austria; Roche, Luxembourg; Roche Registration, Austria; Roche Pharma Schweiz, Switzerland - Trazimera
Pfizer, Netherlands
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.